研究单位：[1]Department of Oncology, The Second Xiangya Hospital, Central South University Recruiting Changsha, Hunan, China, 410011[2]Shanghai Chest Hospital[3]West China Hospital[4]Hunan Cancer Hospital[5]The Third Xiangya Hospital of Central South University[6]The First Affiliated Hospital of Xiamen University[7]Second Affiliated Hospital, School of Medicine, Zhejiang University[8]China-Japan Friendship Hospital[9]Fudan University[10]Jiangxi Provincial Cancer Hospital[11]First Affiliated Hospital of Kunming Medical University[12]Loudi Central Hospital[13]ZhuZhou Central Hospital[14]Xiangtan Central Hospital[15]First People's Hospital of Chenzhou[16]Yueyang Central Hospital[17]Yongzhou Central Hospital[18]The First Affiliated Hospital of University of South China[19]Hunan Provincial People's Hospital[20]Shaoyang Central Hospital[21]Yiyang Central Hospital[22]Changsha Central Hospital[23]The first people's hospital of Guiyang[24]Wuhan Union Hospital, China[25]Renmin Hospital of Wuhan University[26]The First People's Hospital of Changde[27]Zhuzhou Second Hospital[28]First Hospital of Changsha[29]Hengyang Central Hospital[30]Huaihua first people's Hospital[31]The First People's Hospital of Xiangtan[32]University of South China Affiliated Nanhua Hospital[33]Xiangxi Autonomous Prefecture People's Hospital[34]People's Hospital of Zhangjiajie[35]Second People's Hospital Of Huaihua[36]Hunan Academy of Traditional Chinese Medicine Affiliated Hospital[37]The Third Hospital of Changsha[38]Xiangya Changde Hospital[39]Changsha County first People's Hospital[40]Hunan Provincial Straight Hospital of Traditional Chinese Medicine[41]Liuyang Hospital of traditional Chinese Medicine
研究目的：
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients. However, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short term. This study aimed to clarify the molecular indicators that predict the benefits of 3-rd EGFR-TKIs as first-line therapy in NSCLCpatients with EGFR-positive. Further, to clarify their primary drug resistance mechanisms, which is of great significance for the treatment and clinical decision-making of NSCLC disease.
